Botulinum toxin type A for upper limb spasticity after stroke
- PMID: 19951131
- DOI: 10.1586/ern.09.121
Botulinum toxin type A for upper limb spasticity after stroke
Abstract
Spasticity is involuntary overactivity of muscles that occurs following upper motor neuron damage to the brain or spinal cord. Upper limb spasticity is common after stroke and can cause deformity, pain and reduced function. Botulinum toxin type A is a neurotoxin produced by the bacterium Clostridium botulinum that blocks the release of acetylcholine from cholinergic neurons. When given by intramuscular injection it causes temporary local paresis and has become an important component of focal spasticity treatment. Randomized controlled trials have shown that botulinum toxin type A can decrease upper limb spasticity and improve the ease of performing basic upper limb functional activities, such as cleaning the hand or dressing a sleeve. This article will review the pharmacology of botulinum toxin type A and its clinical efficacy when used to treat upper limb spasticity after stroke.
Similar articles
-
BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.Health Technol Assess. 2010 May;14(26):1-113, iii-iv. doi: 10.3310/hta14260. Health Technol Assess. 2010. PMID: 20515600 Clinical Trial.
-
Evaluating the functional outcomes of ultrasound-guided botulinum toxin type A injections using the Euro-musculus approach for upper limb spasticity treatment in post-stroke patients: an observational study.Eur J Phys Rehabil Med. 2018 Oct;54(5):738-744. doi: 10.23736/S1973-9087.18.05086-4. Epub 2018 Feb 7. Eur J Phys Rehabil Med. 2018. PMID: 29422486
-
Botulinum toxin type A for the treatment of the upper limb spasticity after stroke: a meta-analysis.Arq Neuropsiquiatr. 2005 Mar;63(1):30-3. doi: 10.1590/s0004-282x2005000100006. Epub 2005 Apr 13. Arq Neuropsiquiatr. 2005. PMID: 15830061
-
Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence.J Neural Transm (Vienna). 2009 Mar;116(3):319-31. doi: 10.1007/s00702-008-0175-8. Epub 2009 Jan 14. J Neural Transm (Vienna). 2009. PMID: 19142573 Review.
-
Botulinum toxin A treatment of adult upper and lower limb spasticity.Drugs Aging. 2001;18(4):255-62. doi: 10.2165/00002512-200118040-00003. Drugs Aging. 2001. PMID: 11341473 Review.
Cited by
-
Clinical uses of botulinum neurotoxins: current indications, limitations and future developments.Toxins (Basel). 2012 Oct;4(10):913-39. doi: 10.3390/toxins4100913. Epub 2012 Oct 19. Toxins (Basel). 2012. PMID: 23162705 Free PMC article. Review.
-
Disparities in Access to Spasticity Chemodenervation Specialists in the United States: A Retrospective Cross-Sectional Study.Am J Phys Med Rehabil. 2024 Mar 1;103(3):203-207. doi: 10.1097/PHM.0000000000002375. Epub 2023 Nov 22. Am J Phys Med Rehabil. 2024. PMID: 38014884 Free PMC article.
-
A systematic review: efficacy of botulinum toxin in walking and quality of life in post-stroke lower limb spasticity.Syst Rev. 2018 Jan 5;7(1):1. doi: 10.1186/s13643-017-0670-9. Syst Rev. 2018. PMID: 29304876 Free PMC article.
-
Use of botulinum toxin in the neurology clinic.Nat Rev Neurol. 2010 Nov;6(11):624-36. doi: 10.1038/nrneurol.2010.149. Epub 2010 Oct 12. Nat Rev Neurol. 2010. PMID: 21045798 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical